ClinicalTrials.gg
RecruitingNCT06131801Updated Oct 29, 2026

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

An observational study in Hematologic Malignancy, Leukemia and Lymphoma, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 6 sites in United States. Open to participants aged 0 Years to 38 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Children's Hospital Medical Center, Cincinnati · Observational

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Oct 29, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
30
Ages
0 Years to 38 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 823 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 277 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Planned enrollment
125th of 157
30 · median 150
Started
2023
with 35 others
Observational
157 of 823
56 open now
Primary completion
2026-12
later than 76 of 274 live
Registered
722nd of 823
by date

Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is the 125th largest by planned enrollment of the 157 observational ones that give a count, is one of 36 that started in 2023, is one of 157 observational ones, reaches primary completion later than 76 of the 274 other live ones, and was the 722nd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 0 Years to 38 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 823 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.

Primary Objectives

  • To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution

Secondary Objectives

  • To evaluate the safety of crushed venetoclax tablets administered as an oral solution
  • To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors
  • To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)
  • To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution
Read the detailed description

Peripheral blood will be drawn at multiple time points to evaluate venetoclax pharmacokinetics in patients who are receiving venetoclax solution made from crushed tablets as part of their oncology treatment.

03

Conditions studied

  • Hematologic Malignancy
  • Leukemia
  • Lymphoma
  • Acute Lymphocytic Leukemia
  • ALL
  • Acute Myelogenous Leukemia
  • AML
  • Chronic Myelogenous Leukemia
  • CML
  • Myeloproliferative Neoplasm
  • Non Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Burkitt Lymphoma
  • T-cell Lymphoma
  • B Cell Lymphoma
  • Peripheral T Cell Lymphoma
  • Cutaneous B-Cell Lymphoma

Keywords

  • Venetoclax
  • Pediatric AML
  • Pediatric Relapsed/Refractory AML
04

Who can participate

Ages eligible
0 Years to 38 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.

Patients must be \<39 years of age at time of study enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Patients must be \<39 years of age at time of study enrollment
  • Diagnosis: Patients may have a diagnosis of any hematologic
  • Central access: Patients must have an existing venous or arterial access line for PK blood draws
  • Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment
  • Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
  • Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.

Exclusion criteria

Exclusion Criteria:

  • Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.
  • Males or females of may not participate unless they have agreed to use an effective method while on study treatment and for six months following completion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Children and Young Adults

    Children and Young Adults who are prescribed venetoclax made from crushed tablets as part of their clinical care.

    Other: 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.

Interventions

  • Other1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.

    Participants will receive Venetoclax as prescribed by their treating provider as part of their clinical care.

06

What researchers measure

Primary outcomes

  1. Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)

    PK parameters of venetoclax will be described in peripheral blood including: the observed peak plasma concentration (Cmax)

    Time frame: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

  2. Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)

    PK parameters of venetoclax will be described in peripheral blood including: the time to peak (Tmax)

    Time frame: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

  3. Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)

    PK parameters of venetoclax will be described in peripheral blood including: the apparent terminal phase elimination rate constant (β)

    Time frame: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

  4. Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)

    PK parameters of venetoclax will be described in peripheral blood including: the terminal-phase elimination half-life (T1/2)

    Time frame: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

  5. Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)

    PK parameters of venetoclax will be described in peripheral blood including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞)

    Time frame: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

  6. Clearance (CL) as measured by PK sampling (Peripheral Blood; Required)

    PK parameters of venetoclax will be described in peripheral blood including: oral clearance (CL/F) of venetoclax

    Time frame: Blood will be collected on one PK day between Days 5-12 after completion of the venetoclax dose ramp-up : within 1hr prior to the administration of venetoclax, then 2hrs, 5hrs, 12hrs, 18hrs and 24hrs after the administration of venetoclax.

  7. Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)

    PK parameters of venetoclax will be described in cerebral spinal fluid including: the observed peak plasma concentration (Cmax)

    Time frame: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

  8. Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)

    PK parameters of venetoclax will be described in cerebral spinal fluid including: the time to peak (Tmax)

    Time frame: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

  9. Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)

    PK parameters of venetoclax will be described in cerebral spinal fluid including: the apparent terminal phase elimination rate constant (β)

    Time frame: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

  10. Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)

    PK parameters of venetoclax will be described in cerebral spinal fluid including: the terminal-phase elimination half-life (T1/2)

    Time frame: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

  11. Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)

    PK parameters of venetoclax will be described in cerebral spinal fluid including: the areas under plasma concentration curve (AUC) over a 24-hour dose interval (AUC0-24) or for infinite time (AUC0-∞)

    Time frame: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

  12. Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional)

    PK parameters of venetoclax will be described in cerebral spinal fluid including: oral clearance (CL/F)

    Time frame: Around Days 8, 15, 22, and/or 28, all +/- 3 days. Not all patients will have CSF collected at these time points.

07

Study locations

5 of 6 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

Of 164 non-industry observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's planned 36 months is below that.

Counting every sponsor, half of 186 studies reached it within 74 months; a quarter within 34 and three quarters within 322.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Nov 14, 2023
StartActual
Nov 15, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. Children's Hospital of Philadelphia is now Recruiting
Show site
  • Children's Healthcare of Atlanta - Arthur M. Blank Hospital · Atlanta, United States
across 2 updates, Oct 1, 2026 – Oct 29, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Texas Children's Hospital · Houston, United StatesContact added (no phone or email listed)
  • Children's Hospital of Wisconsin · Milwaukee, United StatesContact person changed (no phone or email listed)
Oct 1, 2026
Show all 2 updates
  1. Oct 29, 2026
    Children's Hospital of Philadelphia is now Recruiting
    + 1 other change: verification date
  2. Oct 1, 2026
    1 site added
    Show site
    • Children's Healthcare of Atlanta - Arthur M. Blank Hospital · Atlanta, United States
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Texas Children's Hospital · Houston, United StatesContact added (no phone or email listed)
    • Children's Hospital of Wisconsin · Milwaukee, United StatesContact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06131801
Responsible party
Sponsor
First posted
Nov 14, 2023
Start date
Nov 15, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Site Public Contact
Contact
cancer@cchmc.org
(513) 636-2799
Lauren Pommert, MD
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion